W.H. Cornerstone Investments Inc. Sells 99 Shares of Eli Lilly and Company $LLY

W.H. Cornerstone Investments Inc. cut its position in Eli Lilly and Company (NYSE:LLY) by 13.7% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 623 shares of the company’s stock after selling 99 shares during the quarter. W.H. Cornerstone Investments Inc.’s holdings in Eli Lilly and Company were worth $485,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Wealth Preservation Advisors LLC bought a new stake in Eli Lilly and Company in the 1st quarter worth approximately $27,000. Blume Capital Management Inc. increased its stake in shares of Eli Lilly and Company by 46.7% in the second quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after acquiring an additional 14 shares during the period. IMG Wealth Management Inc. purchased a new stake in Eli Lilly and Company in the 2nd quarter worth $35,000. TD Capital Management LLC boosted its stake in Eli Lilly and Company by 129.2% during the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after buying an additional 31 shares during the last quarter. Finally, Family CFO Inc purchased a new position in Eli Lilly and Company during the 2nd quarter valued at about $54,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on LLY shares. Cantor Fitzgerald increased their target price on Eli Lilly and Company from $925.00 to $985.00 and gave the stock an “overweight” rating in a research note on Friday, October 31st. Wall Street Zen raised shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 1st. Leerink Partners raised shares of Eli Lilly and Company from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $886.00 to $1,104.00 in a research note on Monday. Weiss Ratings restated a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Wednesday, October 8th. Finally, BMO Capital Markets lifted their target price on Eli Lilly and Company from $930.00 to $1,100.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $999.32.

Eli Lilly and Company Stock Up 1.1%

Shares of NYSE:LLY traded up $10.79 during midday trading on Thursday, reaching $1,028.57. The company had a trading volume of 1,144,254 shares, compared to its average volume of 4,058,430. The business’s 50 day moving average price is $815.33 and its 200 day moving average price is $778.16. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,032.95. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The stock has a market cap of $972.39 billion, a PE ratio of 67.23, a P/E/G ratio of 1.21 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. During the same period in the previous year, the company posted $1.18 EPS. The firm’s quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be issued a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.